Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer And Kythera Strike Licensing Deal in Aesthetic Dermatology

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer's Intendis skin care unit bets on a niche drug that is likely to depend on out-of-pocket payments.

You may also be interested in...



Botox Reimbursement Training Is Driving Factor In Allergan Settlement With DOJ

Allergen will pay $600 million for promoting the drug for headache and spasticity; government says company taught physicians how to bill for off-label uses.

Medical Dermatology Gets Under VCs' Skin

In the pharmaceutical industry, dermatology is the new ophthalmology. Like ophtho, dermatology has long been viewed as a pharmaceutical backwater dogged by a diverse set of problems, including a fragmented market, drug delivery challenges, and less than effective therapies. Today's market forces, however, are driving Big Pharma into a more specialized direction, and in the past three years, many - if not all - Big Pharmas have reoriented their pipelines, refocusing on areas of high unmet medical need in the hopes of identifying novel drugs that have a greater chance of passing muster with regulators and succeeding in the marketplace. Freed from the need to pursue blockbuster products, dermatology assets are suddenly more attractive.

Intendis: Mid-Sized Specialist Spawns Small Specialist

In dermatology offshoot Intendis, Schering AG has created the ideal European crossbreed: a group with the management experience associated with spin-outs, and a revenue-generating side more typical of specialty pharma. The snag: Schering's retaining full ownership--for now.

Topics

UsernamePublicRestriction

Register

PS071255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel